Last-Hope drug access opens for breast cancer patients
NCT ID NCT05038631
Summary
This program provides access to the breast cancer drug ribociclib for patients who have exhausted standard treatments or need it as additional therapy after surgery. It's designed for people with advanced cancer that has stopped responding to available options, or for early-stage patients needing extra treatment alongside standard hormone therapy. The program serves as a bridge when patients can't join clinical trials or when no other suitable treatments exist.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-••••
Conditions
Explore the condition pages connected to this study.